2022-06-22 |
Wettig Thane |
officer: Chief Commercial Officer |
91,294.0 |
F-InKind |
D |
655.0 |
11.42 |
7,480.10 |
|
2022-06-16 |
Henderson Jeffrey William |
director |
25,684.0 |
A-Award |
A |
25,684.0 |
9.00 |
231,156.00 |
|
2022-06-16 |
Henderson Jeffrey William |
director |
33,577.0 |
A-Award |
A |
15,777.0 |
0.00 |
0.00 |
|
2022-06-16 |
Ho Maykin |
director |
25,684.0 |
A-Award |
A |
25,684.0 |
9.00 |
231,156.00 |
|
2022-06-16 |
Ho Maykin |
director |
31,732.0 |
A-Award |
A |
15,777.0 |
0.00 |
0.00 |
|
2022-06-16 |
EDWARDS JEFFREY L |
director |
25,684.0 |
A-Award |
A |
25,684.0 |
9.00 |
231,156.00 |
|
2022-06-16 |
EDWARDS JEFFREY L |
director |
33,577.0 |
A-Award |
A |
15,777.0 |
0.00 |
0.00 |
|
2022-06-16 |
Cravatt Benjamin |
director |
25,684.0 |
A-Award |
A |
25,684.0 |
9.00 |
231,156.00 |
|
2022-06-16 |
Cravatt Benjamin |
director |
24,391.0 |
A-Award |
A |
15,777.0 |
0.00 |
0.00 |
|
2022-06-16 |
Brennan Aoife |
director |
25,684.0 |
A-Award |
A |
25,684.0 |
9.00 |
231,156.00 |
|
2022-06-16 |
Brennan Aoife |
director |
24,391.0 |
A-Award |
A |
15,777.0 |
0.00 |
0.00 |
|
2022-06-16 |
Lema Gerald |
director |
25,684.0 |
A-Award |
A |
25,684.0 |
9.00 |
231,156.00 |
|
2022-06-16 |
Lema Gerald |
director |
20,477.0 |
A-Award |
A |
15,777.0 |
0.00 |
0.00 |
|
2022-06-16 |
Blaug Suzanne |
director |
25,684.0 |
A-Award |
A |
25,684.0 |
9.00 |
231,156.00 |
|
2022-06-16 |
Blaug Suzanne |
director |
29,825.0 |
A-Award |
A |
15,777.0 |
0.00 |
0.00 |
|
2022-06-16 |
Schoeneck James A |
director |
25,684.0 |
A-Award |
A |
25,684.0 |
9.00 |
231,156.00 |
|
2022-06-16 |
Schoeneck James A |
director |
20,477.0 |
A-Award |
A |
15,777.0 |
0.00 |
0.00 |
|
2022-06-06 |
Chung Christine |
officer: SVP, China Operations |
244,002.0 |
F-InKind |
D |
1,850.0 |
9.50 |
17,575.00 |
|
2022-06-06 |
Wettig Thane |
officer: Chief Commercial Officer |
89,961.0 |
F-InKind |
D |
360.0 |
9.50 |
3,420.00 |
|
2022-06-06 |
Conterno Enrique A |
director, officer: Chief Executive Officer |
301,940.0 |
F-InKind |
D |
1,772.0 |
9.50 |
16,834.00 |
|
2022-06-01 |
Eisner Mark |
officer: Chief Medical Officer |
149,800.0 |
F-InKind |
D |
1,141.0 |
9.61 |
10,965.01 |
|
2022-04-07 |
Conterno Enrique A |
director, officer: Chief Executive Officer |
303,712.0 |
F-InKind |
D |
1,311.0 |
12.73 |
16,689.03 |
|
2022-03-31 |
Eisner Mark |
officer: Chief Medical Officer |
150,941.0 |
F-InKind |
D |
6,442.0 |
12.02 |
77,432.84 |
|
2022-03-31 |
Chung Christine |
officer: SVP, China Operations |
245,852.0 |
F-InKind |
D |
4,682.0 |
12.02 |
56,277.64 |
|
2022-03-22 |
Wettig Thane |
officer: Chief Commercial Officer |
90,321.0 |
F-InKind |
D |
655.0 |
13.31 |
8,718.05 |
|
2022-03-07 |
Wettig Thane |
officer: Chief Commercial Officer |
90,976.0 |
F-InKind |
D |
1,706.0 |
12.69 |
21,649.14 |
|
2022-03-07 |
Conterno Enrique A |
director, officer: Chief Executive Officer |
305,023.0 |
F-InKind |
D |
7,081.0 |
12.69 |
89,857.89 |
|
2022-03-07 |
Chung Christine |
officer: SVP, China Operations |
250,534.0 |
F-InKind |
D |
3,905.0 |
12.69 |
49,554.45 |
|
2022-03-01 |
Eisner Mark |
officer: Chief Medical Officer |
157,383.0 |
F-InKind |
D |
756.0 |
13.62 |
10,296.72 |
|
2022-02-14 |
Graham Juan |
officer: Chief Financial Officer |
37,500.0 |
A-Award |
A |
37,500.0 |
15.60 |
585,000.00 |
|
2022-02-14 |
Graham Juan |
officer: Chief Financial Officer |
58,900.0 |
A-Award |
A |
22,500.0 |
0.00 |
0.00 |
|
2022-02-14 |
Wettig Thane |
officer: Chief Commercial Officer |
75,000.0 |
A-Award |
A |
75,000.0 |
15.60 |
1,170,000.00 |
|
2022-02-14 |
Wettig Thane |
officer: Chief Commercial Officer |
92,682.0 |
A-Award |
A |
45,000.0 |
0.00 |
0.00 |
|
2022-02-14 |
Eisner Mark |
officer: Chief Medical Officer |
100,000.0 |
A-Award |
A |
100,000.0 |
15.60 |
1,560,000.00 |
|
2022-02-14 |
Eisner Mark |
officer: Chief Medical Officer |
158,139.0 |
A-Award |
A |
60,000.0 |
0.00 |
0.00 |
|
2022-02-14 |
Conterno Enrique A |
director, officer: Chief Executive Officer |
298,000.0 |
A-Award |
A |
298,000.0 |
15.60 |
4,648,800.00 |
|
2022-02-14 |
Conterno Enrique A |
director, officer: Chief Executive Officer |
312,104.0 |
A-Award |
A |
179,400.0 |
0.00 |
0.00 |
|
2022-02-14 |
Chung Christine |
officer: SVP, China Operations |
75,000.0 |
A-Award |
A |
75,000.0 |
15.60 |
1,170,000.00 |
|
2022-02-14 |
Chung Christine |
officer: SVP, China Operations |
254,439.0 |
A-Award |
A |
45,000.0 |
0.00 |
0.00 |
|
2022-01-06 |
Conterno Enrique A |
director, officer: Chief Executive Officer |
132,704.0 |
F-InKind |
D |
1,536.0 |
13.93 |
21,396.48 |
|
2022-01-03 |
Chung Christine |
officer: SVP, China Operations |
209,439.0 |
F-InKind |
D |
5,284.0 |
14.82 |
78,308.88 |
|
2022-01-03 |
Eisner Mark |
officer: Chief Medical Officer |
98,139.0 |
F-InKind |
D |
7,043.0 |
14.82 |
104,377.26 |
|
2021-12-22 |
Wettig Thane |
officer: Chief Commercial Officer |
47,682.0 |
F-InKind |
D |
517.0 |
14.97 |
7,739.49 |
|
2021-12-06 |
Chung Christine |
officer: SVP, China Operations |
214,723.0 |
F-InKind |
D |
2,668.0 |
14.19 |
37,858.92 |
|
2021-12-01 |
Eisner Mark |
officer: Chief Medical Officer |
105,182.0 |
F-InKind |
D |
4,338.0 |
12.65 |
54,875.70 |
|
2021-10-06 |
Conterno Enrique A |
director, officer: Chief Executive Officer |
134,239.0 |
F-InKind |
D |
1,859.0 |
10.20 |
18,961.80 |
|
2021-10-04 |
Chung Christine |
officer: SVP, China Operations |
32,360.0 |
A-Award |
A |
32,360.0 |
9.93 |
321,334.80 |
|
2021-10-04 |
Chung Christine |
officer: SVP, China Operations |
217,391.0 |
A-Award |
A |
54,170.0 |
0.00 |
0.00 |
|
2021-10-04 |
Eisner Mark |
officer: Chief Medical Officer |
44,520.0 |
A-Award |
A |
44,520.0 |
9.93 |
442,083.60 |
|
2021-10-04 |
Eisner Mark |
officer: Chief Medical Officer |
109,520.0 |
A-Award |
A |
74,520.0 |
0.00 |
0.00 |
|
2021-09-22 |
Wettig Thane |
officer: Chief Commercial Officer |
48,196.0 |
F-InKind |
D |
620.0 |
10.18 |
6,311.60 |
|
2021-09-15 |
KEARNS THOMAS F JR |
director |
39,764.0 |
S-Sale |
D |
13,100.0 |
11.58 |
151,707.17 |
|
2021-09-07 |
Chung Christine |
officer: SVP, China Operations |
165,251.0 |
F-InKind |
D |
2,030.0 |
12.41 |
25,192.30 |
|
2021-09-07 |
Cotroneo Pat |
officer: SVP, Finance and CFO |
274,536.0 |
F-InKind |
D |
2,141.0 |
12.41 |
26,569.81 |
|
2021-09-07 |
Graham Juan |
officer: Chief Financial Officer |
196,000.0 |
A-Award |
A |
196,000.0 |
12.41 |
2,432,360.00 |
|
2021-09-07 |
Graham Juan |
officer: Chief Financial Officer |
36,400.0 |
A-Award |
A |
35,000.0 |
0.00 |
0.00 |
|
2021-08-26 |
Wettig Thane |
officer: Chief Commercial Officer |
48,816.0 |
P-Purchase |
A |
3,100.0 |
11.53 |
35,743.00 |
|
2021-07-06 |
Conterno Enrique A |
director, officer: Chief Executive Officer |
136,098.0 |
F-InKind |
D |
1,859.0 |
25.06 |
46,586.54 |
|
2021-06-22 |
Wettig Thane |
officer: Chief Commercial Officer |
45,716.0 |
F-InKind |
D |
2,593.0 |
27.65 |
71,696.45 |
|
2021-06-15 |
Cotroneo Pat |
officer: SVP, Finance and CFO |
276,677.0 |
S-Sale |
D |
4,053.0 |
25.62 |
103,837.86 |
|
2021-06-07 |
Chung Christine |
officer: SVP, China Operations |
165,251.0 |
F-InKind |
D |
2,030.0 |
22.90 |
46,487.00 |
|
2021-06-07 |
Cotroneo Pat |
officer: SVP, Finance and CFO |
280,730.0 |
F-InKind |
D |
2,141.0 |
22.90 |
49,028.90 |
|
2021-05-26 |
Brennan Aoife |
director |
7,800.0 |
A-Award |
A |
7,800.0 |
20.86 |
162,708.00 |
|
2021-05-26 |
Brennan Aoife |
director |
8,614.0 |
A-Award |
A |
4,700.0 |
0.00 |
0.00 |
|
2021-05-26 |
KEARNS THOMAS F JR |
director |
52,864.0 |
A-Award |
A |
4,700.0 |
0.00 |
0.00 |
|
2021-05-26 |
KEARNS THOMAS F JR |
director |
7,800.0 |
A-Award |
A |
7,800.0 |
20.86 |
162,708.00 |
|
2021-05-26 |
Schoeneck James A |
director |
14,100.0 |
A-Award |
A |
4,700.0 |
0.00 |
0.00 |
|
2021-05-26 |
Schoeneck James A |
director |
7,800.0 |
A-Award |
A |
7,800.0 |
20.86 |
162,708.00 |
|
2021-05-26 |
RIGGS RORY B |
director |
395,750.0 |
A-Award |
A |
4,700.0 |
0.00 |
0.00 |
|
2021-05-26 |
RIGGS RORY B |
director |
7,800.0 |
A-Award |
A |
7,800.0 |
20.86 |
162,708.00 |
|
2021-05-26 |
Cravatt Benjamin |
director |
8,614.0 |
A-Award |
A |
4,700.0 |
0.00 |
0.00 |
|
2021-05-26 |
Cravatt Benjamin |
director |
7,800.0 |
A-Award |
A |
7,800.0 |
20.86 |
162,708.00 |
|
2021-05-26 |
EDWARDS JEFFREY L |
director |
7,800.0 |
A-Award |
A |
7,800.0 |
20.86 |
162,708.00 |
|
2021-05-26 |
Henderson Jeffrey William |
director |
7,800.0 |
A-Award |
A |
7,800.0 |
20.86 |
162,708.00 |
|
2021-05-26 |
Ho Maykin |
director |
15,955.0 |
A-Award |
A |
4,700.0 |
0.00 |
0.00 |
|
2021-05-26 |
Ho Maykin |
director |
7,800.0 |
A-Award |
A |
7,800.0 |
20.86 |
162,708.00 |
|
2021-05-26 |
Lema Gerald |
director |
9,400.0 |
A-Award |
A |
4,700.0 |
0.00 |
0.00 |
|
2021-05-26 |
Lema Gerald |
director |
7,800.0 |
A-Award |
A |
7,800.0 |
20.86 |
162,708.00 |
|
2021-05-26 |
Kurkijarvi Kalevi |
director |
37,800.0 |
A-Award |
A |
4,700.0 |
0.00 |
0.00 |
|
2021-05-26 |
Kurkijarvi Kalevi |
director |
7,800.0 |
A-Award |
A |
7,800.0 |
20.86 |
162,708.00 |
|
2021-05-26 |
Blaug Suzanne |
director |
14,048.0 |
A-Award |
A |
4,700.0 |
0.00 |
0.00 |
|
2021-05-26 |
Blaug Suzanne |
director |
7,800.0 |
A-Award |
A |
7,800.0 |
20.86 |
162,708.00 |
|
2021-05-26 |
EDWARDS JEFFREY L |
director |
17,800.0 |
A-Award |
A |
4,700.0 |
0.00 |
0.00 |
|
2021-05-26 |
Henderson Jeffrey William |
director |
17,800.0 |
A-Award |
A |
4,700.0 |
0.00 |
0.00 |
|
2021-03-11 |
KEARNS THOMAS F JR |
director |
166,164.0 |
M-Exempt |
A |
18,000.0 |
35.02 |
630,360.00 |
|
2021-03-11 |
KEARNS THOMAS F JR |
director |
0.0 |
M-Exempt |
D |
12,000.0 |
3.50 |
42,000.00 |
|
2021-03-11 |
KEARNS THOMAS F JR |
director |
148,164.0 |
S-Sale |
D |
18,000.0 |
35.02 |
630,360.00 |
|
2021-03-08 |
Chung Christine |
officer: SVP, China Operations |
166,597.0 |
F-InKind |
D |
5,679.0 |
33.37 |
189,508.23 |
|
2021-03-08 |
Cotroneo Pat |
officer: SVP, Finance and CFO |
282,187.0 |
F-InKind |
D |
5,657.0 |
33.37 |
188,774.09 |
|
2021-03-08 |
Kouchakji Elias |
officer: SVP, Clinical Dev, Drug Safety |
147,346.0 |
F-InKind |
D |
5,221.0 |
33.37 |
174,224.77 |
|
2021-02-24 |
Wettig Thane |
officer: Chief Commercial Officer |
47,150.0 |
A-Award |
A |
16,500.0 |
0.00 |
0.00 |
|
2021-02-24 |
Wettig Thane |
officer: Chief Commercial Officer |
32,100.0 |
A-Award |
A |
32,100.0 |
53.01 |
1,701,621.00 |
|
2021-02-24 |
Kouchakji Elias |
officer: SVP, Clinical Dev, Drug Safety |
152,567.0 |
A-Award |
A |
20,800.0 |
0.00 |
0.00 |
|
2021-02-24 |
Kouchakji Elias |
officer: SVP, Clinical Dev, Drug Safety |
39,900.0 |
A-Award |
A |
39,900.0 |
53.01 |
2,115,099.00 |
|
2021-02-24 |
Cotroneo Pat |
officer: SVP, Finance and CFO |
287,844.0 |
A-Award |
A |
21,700.0 |
0.00 |
0.00 |
|
2021-02-24 |
Cotroneo Pat |
officer: SVP, Finance and CFO |
41,700.0 |
A-Award |
A |
41,700.0 |
53.01 |
2,210,517.00 |
|
2021-02-24 |
Chung Christine |
officer: SVP, China Operations |
172,276.0 |
A-Award |
A |
21,700.0 |
0.00 |
0.00 |
|
2021-02-24 |
Chung Christine |
officer: SVP, China Operations |
41,700.0 |
A-Award |
A |
41,700.0 |
53.01 |
2,210,517.00 |
|
2021-02-24 |
Conterno Enrique A |
director, officer: Chief Executive Officer |
137,273.0 |
A-Award |
A |
82,000.0 |
0.00 |
0.00 |
|
2021-02-24 |
Conterno Enrique A |
director, officer: Chief Executive Officer |
164,000.0 |
A-Award |
A |
164,000.0 |
53.01 |
8,693,640.00 |
|